Biology and Medicine, 1 (3): 39-43, 2009 eISSN: 09748369, www.biolmedonline.com The influence of chloroquine administration on antioxidant levels, oxidant marker and total cholesterol in Wistar rats AC Achudume Institute of Ecology and Environmental Studies, Obafemi Awolowo University, Ile-Ife, Nigeria. Abstract This study was undertaken to determine some biochemical cha
Doi:10.1016/j.rdc.2007.01.002Division of Rheumatology and Immunology, Duke University Medical Center, Box 3535 Trent Drive, Durham, NC 27710, USA Systemic lupus erythematosus (SLE) primarily aﬀects women in their reproductive years, making the issue of pregnancy important to many pa-tients. There are an estimated 4500 pregnancies in women with SLE eachyear in the United States The impact of pregnancy on SLE activity has been debated in the litera- ture, but the majority of studies endorse an increase in disease activity dur-ing pregnancy. In some patients, this will mean a dramatic worsening ofsymptoms that can be life threatening. Most patients, however, will havea modest increase in symptoms making pregnancy uncomfortable but notaﬀecting their long-term survival.
Women with SLE have complicated pregnancies: one third will result in a cesarean section, 33% will have preterm birth, and more than 20% will becomplicated by preeclampsia Increased lupus activity, particularly be-fore conception and early in pregnancy, signiﬁcantly increases the risks forthese complications. For this reason, timing pregnancy to coincide with a pe-riod of SLE quiescence is a worthy goal.
This article will address the impact of pregnancy on SLE activity, of SLE activity on pregnancy outcome, and the treatment of women with SLE tominimize these eﬀects.
Systemic lupus erythematosus activity during pregnancy Whether SLE activity increases during pregnancy has been debated widely in the literature. In murine models, increasing doses of estrogen,like those seen in pregnancy, promote physiologic and immunologic changesassociated with increased lupus activity . Diﬀerent methods to deter-mine a ﬂare and active lupus were used in many of the cohort studies ofSLE pregnancy in the literature. Therefore, it is diﬃcult to draw clear Megan Clowse is a BIRCWH Scholar: NIH grant number 5K12-HD-043446.
E-mail address: 0889-857X/07/$ - see front matter Ó 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.rdc.2007.01.002 conclusions about the impact of pregnancy on SLE activity. Several smallstudies that matched pregnant lupus patients with nonpregnant lupuspatients found no signiﬁcant increase in SLE activity during pregnancyHowever, more recent studies have found a two- to threefold increasein SLE activity during pregnancy () . Based on these studies, itappears that between 35% and 70% of all pregnancies will have measurableSLE activity, with most studies showing the risk to be between 40% and50% The risk for a moderate to severe ﬂare is lower and rangesbetween 15% and 30% .
The risk of lupus ﬂare is increased drastically if the woman has had active lupus in the 6 months before pregnancy. Two hundred sixty-ﬁve pregnanciesto women with lupus were seen in the Hopkins Lupus Pregnancy Cohortbetween 1987 and 2002. In this cohort, the risk for signiﬁcant SLE activityduring pregnancy was 7.25-fold higher if the patient had recently active lupusbefore conception (58% versus 8%, P!.001) . Other studies have founda twofold increase in risk for lupus ﬂare during pregnancy among womenwith active SLE at conception . Other risk factors for increased lupusactivity in pregnancy include the discontinuation of antimalarial therapyand a history of highly active lupus in the years before pregnancy .
Fortunately, the majority of SLE activity in pregnancy is not severe. In most studies, skin, joint, and constitutional symptoms are most commonly Box 1. Impact of pregnancy on systemic lupus erythematosusactivity Pregnancy probably increases lupus activity: About 50% of women will have measurable SLE activity during Most of the disease activity will be mild to moderate15% to 30% of women will have highly active SLE in pregnancy Most common types of SLE activity in pregnancy: Cutaneous diseaseArthritisHematologic disease Risk factors for increased lupus activity: Active lupus within the 6 months before conceptionMultiple flares in the years before conceptionDiscontinuation of hydroxychloroquine reported. The risk for skin disease ranges from 25% to 90%, depending onthe severity measured . The rates for arthritis during pregnancy aresimilarly disparate between studies, based on the severity measured. How-ever, 2 large cohorts show a 20% risk of signiﬁcant arthritis, althoughmany more women will have an increase in less-severe joint pain Hema-tologic disease, in particular thrombocytopenia, is also common duringpregnancy, with the risk ranging from 10% to 40% in diﬀerent cohorts The risk for lupus nephritis during lupus ranges from 4% to 30%, based on the cohort characteristics and the deﬁnition of lupus nephritis. Women with a prior history of lupus nephritis have 20% to30% risk of relapse during pregnancy . For women who have worsen-ing renal function because of SLE nephritis during pregnancy, an estimated25% had continuing renal damage after pregnancy, despite aggressive ther-apy . Fortunately, very few women require lifelong dialysis.
Timing of systemic lupus erythematosus ﬂares in pregnancy Lupus ﬂares can occur at any time during pregnancy, as well as in the sev- eral months after delivery. Although several studies have reported on thetiming of activity in trimesters, a consistent pattern is not apparent. It is important to keep in mind, however, that lupus patients re-main at risk of ﬂare in the months after delivery Impact of systemic lupus erythematosus activity on pregnancy outcome Overall, about 20% of pregnancies to women with SLE will end with a miscarriage or stillbirth The risk of miscarriage (a pregnancy loss be-fore 20 weeks gestation) is not markedly elevated over the general popula-tion. The risk of stillbirth (a pregnancy loss after 20 weeks gestation),however, is elevated in several studies. The two most important risk factorsfor pregnancy loss are increased lupus activity and antiphospholipid syn-drome (APS). In a Greek cohort of SLE pregnancies, six of eight (75%)pregnancies with high-activity SLE resulted in a fetal loss, whereas only14% of pregnancies without active lupus and 5% of non-SLE pregnanciesended with a loss In the Hopkins Lupus Pregnancy Cohort, increasedlupus activity did not increase the risk for miscarriage, but the stillbirthrate was threefold higher () The timing of lupus activity aﬀectsthe pregnancy loss rate, with activity early in pregnancy being the mostdangerous. Proteinuria, thrombocytopenia, and hypertension in the ﬁrsttrimester are each independent risk factors for pregnancy loss. A womanwith any of these risk factors has a 30% to 40% chance of suﬀering a preg-nancy loss .
Table 1Increased lupus activity in pregnancy increases pregnancy complications Late preterm (28 to 37 weeks’ gestation) (!10th percentile weightfor gestational age) Data from Clowse MEB, Magder L, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52(2):514–21.
The risk for preterm birth (delivery before 37 weeks gestation) is estimated to be 33% in all lupus pregnancies In a population-based study of 555lupus deliveries in California, 21% were preterm, which was almost sixfoldhigher than the rate in healthy women . Among cohorts at tertiary referralcenters, however, the rate tends to be higher, ranging from 20% to 54%Preterm premature rupture of membranes (PPROM) isa prominent cause of preterm birth among lupus patients Althoughmost of the preterm births are spontaneous, a signiﬁcant proportion ofthem are induced to protect the health of either the mother or the baby .
Risk factors for preterm birth include lupus activity before and during pregnancy, higher prednisone dose, and hypertension. In the HopkinsLupus Pregnancy Cohort, 66% of pregnancies with active lupus were deliv-ered preterm versus 32% of pregnancies without active lupus (P!.05) (seeBabies born before 28 weeks’ gestation are at highest risk forlong-term medical complications and neonatal death. Within this cohort,17% of all pregnancies with active SLE were born between 24 and 28 weeks’gestation, but only 6% of those without SLE activity were born during thisrisky period (P ¼ .09) .
In women without SLE, an estimated one third of spontaneous preterm births are associated with infection within the uterus. The inﬂammation as-sociated with chorioamnitis is postulated to promote dissolution of the am-niotic sac, ripening of the cervix, and uterine contractions, which all lead topreterm birth. Unfortunately, no data have been published about the rate ofchorioamnititis in SLE pregnancies. Placenta studies, however, do not showincreased rates for infection on pathology We can hypothesize that theinﬂammation seen in active lupus may have a similar eﬀect on the utero-placental unit, thereby increasing preterm labor and rupture of membranes.
Research to study this hypothesis is in its infancy, but in the future we hopethat the role of inﬂammation in preterm birth will be more clearly elucidated. Once this mechanism is understood, improved methods of ther-apy may be developed.
Any study of low birth weight babies, in particular among lupus pregnan- cies, is complicated by the high rate of preterm birth. Therefore, the correc-tion of the weight by gestational age is generally used. A small forgestational age (SGA) baby weighs less than the tenth percentile based onnational norms On average, 9.4% of all SLE pregnancy cohort birthswere SGA, comparable to what would be expected in the general population. However, some cohorts had signiﬁcant increases over the expected rate,with some as high as 35% . Given the relatively small risk for SGA,clear risk factors have not been identiﬁed. When a pregnancy is complicatedby placental insuﬃciency, the baby may grow slowly and fail to gainadequate weight. Placental studies report a higher incidence of thrombosisamong pregnancies aﬀected by SLE For this reason, it is not surprisingthat some SLE pregnancies produce growth-restricted infants.
Preeclampsia is characterized as elevated blood pressure and proteinuria starting in the latter half of pregnancy. Preeclampsia places a woman andher fetus at considerable risk for stroke, preterm birth, and even death. Insevere situations, preeclampsia may evolve into eclampsia with the additionof grand mal seizures in the mother. Deﬁnitive treatment for preeclampsia isdelivery of the pregnancy; once the fetus (and probably more importantlythe placenta) is removed, the hypertension, proteinuria, and risks subside.
Pregnant women with SLE are at increased risk for preeclampsia. Pre- eclampsia complicates 5% to 8% of pregnancies in the United States. How-ever, among lupus pregnancy cohorts, the rate of preeclampsia ranges from13% to 35% . Preeclampsia is thought to arise from vasculardysfunction in the placenta. Several experimental markers for preeclampsia,including sFlt-1 (soluble FMS-like tyrosine kinase) and PIGF (placentalgrowth factor), have been found to correspond to preeclampsia in lupuspatients as they do in women with SLE . Women at particular risk for pre-eclampsia are in their ﬁrst pregnancy, have a history of preeclampsia or renaldisease, have active SLE at conception, have positive anti–double-strandedDNA antibody (dsDNA) or antiribonucleoprotein antibodies, have lowcomplement, are obese, and/or have hypertension ( Among cohorts of patients with a history of lupus nephritis before preg- nancy, pregnancy loss rates range from 8% to 36%, excluding pregnanciesthat are electively terminated . In patients with active lupus Table 2Factors that distinguish between preeclampsia and systemic lupus erythematosus activity (white blood cells, redblood cells, casts) Physical ﬁndings: signs and symptoms of active SLE nephritis in pregnancy, fetal loss occurs in 36% to 52% of the pregnancies. Among patients with prior lupus nephritis but with stable creatinineand minimal proteinuria during pregnancy, 11% to 13% result in a fetal loss. Prematurity occurs in 16% to 75% of pregnancies, with most seriesreporting around 35% to 40% preterm . Although a historyof lupus nephritis does not preclude pregnancy, it does increase the risks forreactivation of lupus activity, preeclampsia, and pregnancy loss.
Distinguishing lupus activity from the signs and symptoms of pregnancy Systemic lupus erythematosus versus pregnancy: signs and symptoms Many of the signs and symptoms of pregnancy can be easily mistaken for signs of active SLE For this reason, when the SLE disease activity Table 3Symptoms of pregnancy that can mimic lupus activity Fatigue that can be debilitating throughout entire pregnancy.
Palmar erythema and a facial blush from increased estrogen.
Melasma: ‘‘mask of pregnancy.’’ A macular, photosensitive hyperpigmented area over cheeks and forehead.
Increased hair growth and thickness during pregnancy.
Hair loss in the weeks to months postpartum.
Increased respiratory rate early in pregnancy from Dyspnea from enlarging uterus late in pregnancy.
Back pain in second and third trimesters.
B Relaxin loosens sacroiliac joint and symphysis pubis B Gravid uterus increases lumbar lordosis.
Joint eﬀusions: noninﬂammatory in lower extremities.
Headache can be part of normal pregnancy or associated Seizures occur in eclampsia.
Cerebral vascular accidents can be caused by preeclampsia or From Tsokos GC, Gordon C, Smolen JS, editors. Systemic lupus erythematosusda compan- ion to rheumatology. St. Louis: Mosby; 2007; with permission.
index (SLEDAI) was modiﬁed for pregnancy, several caveats were includedto rule out pregnancy-related complications, thus allowing for a clearer mea-sure of true SLE activity Symptoms such as severe fatigue, melasma (the‘‘mask of pregnancy’’), postpartum hair loss, increased shortness of breath,arthralgias, and headaches frequently accompany normal pregnancy.
Arthralgias are common among pregnant women because of increased weight as well as the eﬀect of relaxin on the joints. A study comparingpregnant women with and without rheumatoid arthritis documented thateven women without arthritis have signiﬁcant pain. The HAQ (Health As-sessment Questionnaire) score for healthy pregnant women increased from0.02 in the ﬁrst trimester to 0.16 in the second and 0.48 in the third (scoreranges from 0 to 3) Because up to 30% of SLE patients are also aﬀected by ﬁbromyalgia, it is important to distinguish between the aches and pains of ﬁbromyalgia and anarthritis that is accompanied by inﬂammation. There is very limited pub-lished information about the change in ﬁbromyalgia symptoms in preg-nancy. A single study comparing 22 pregnant women with ﬁbromyalgiaand 22 pregnant women without found a signiﬁcant worsening of ﬁbromyal-gia symptoms during pregnancy . Because steroids do not have a role intreating ﬁbromyalgia, they should not be given if inﬂammation is notpresent.
In normal pregnancy, the woman’s blood volume increases by 50%, which alters several laboratory parameters. The hematocrit level frequentlydecreases because of hemodilution. Up to 50% of pregnancies in healthy women may have some degree of anemia. Hemolytic anemia, however, isnot considered normal and could be a sign of a lupus ﬂare or HELLP syn-drome (a severe derivative of preeclampsia with hemolysis, elevated livertests, and low platelets). Mild thrombocytopenia, usually with a plateletcount around 100,000, can occur in up to 8% of healthy pregnancies. Aplatelet count below this, however, is more likely to be from lupus activity,severe preeclampsia, or HELLP syndrome.
The creatinine level normally decreases secondary to the increased glomerular ﬁltration rate required to accommodate the increased blood vol-ume. In fact, a creatinine level that remains stable throughout pregnancyand does not decrease could be a sign of renal insuﬃciency. In womenwith prior renal damage from lupus nephritis, the degree of urine proteinmay increase. This is, again, secondary to increased blood ﬂow throughthe kidneys, resulting in increased tubular ﬂow. Therefore, alarm shouldnot be raised unless baseline proteinuria doubles. Even in healthy pregnan-cies, a small degree of proteinuria (!300 mg/24 hr) can be considered withinthe normal range.
Complement levels (C3 and C4) may decrease with increased lupus activ- ity, because these proteins are consumed in the inﬂammatory process Inpregnancy, however, the complement levels may increase 10% to 50% in re-sponse to increased hepatic protein synthesis Therefore, the utility ofcomplement measurement in pregnancy is unclear. In the Hopkins LupusPregnancy Cohort, half of the pregnancies had hypocomplementemia atsome point. Low complement alone was not particularly predictive of eitherlupus activity or pregnancy outcome. However, the combination of lowcomplement and high-activity lupus led to a three- to ﬁvefold increase inpregnancy loss and preterm birth The anti–double-stranded DNA antibody (dsDNA) is very sensitive for the diagnosis of lupus and can be indicative of increased lupus activity, es-pecially in the kidney. A rising level of dsDNA during pregnancy may cor-respond to increasing lupus activity. In the Hopkins Lupus PregnancyCohort, 43% of women had a positive dsDNA during pregnancy. Womenwith a positive dsDNA had a higher incidence of increased lupus activity(28%) than those without this antibody (16%, P!.05) . However, thisantibody did not predict pregnancy outcomes. Instead, the combinationof a positive dsDNA titer and highly active SLE contributed toward afour- to sixfold increase in perinatal mortality and a two- to threefold de-crease in full-term birth .
The erythrocyte sedimentation rate (ESR) is unreliable in pregnancy be- cause it increases signiﬁcantly in normal pregnancy. The C-reactive protein(CRP), however, may be more useful during pregnancy. In non-SLE preg-nancies, an increased CRP level in the second trimester has been associatedwith preterm birth The CRP does not increase in all pregnancies andmay be more reﬂective of the degree of overall inﬂammation during preg-nancy. In nonpregnant SLE patients, the CRP may increase with a lupus ﬂare The use of CRP has not been systematically tested in SLEpregnancies yet.
Distinguishing lupus nephritis from preeclampsia One of the greatest challenges of caring for pregnant SLE patients is dis- tinguishing between preeclampsia and a lupus nephritis ﬂare. Both presentwith proteinuria, hypertension, and lower extremity edema and may havemore systemic eﬀects as well (see The treatment of these two con-ditions is diﬀerent: preeclampsia will remit with delivery of the fetus, but ac-tive SLE will require immunosuppression.
Preeclampsia is diagnosed when a pregnant woman has a blood pressure O140/90 and proteinuria O0.3 g per 24 hours after 20 weeks’ gestation. Se-vere preeclampsia can be accompanied by severe hypertension (R160/110);microangiopathic hemolytic anemia with thrombocytopenia, anemia, andan elevated lactate dehydrogenase level; liver damage with elevated liver en-zymes and epigastric pain; CNS ischemia causing headache, visual changes,and stroke; and renal pathology with nephrotic range proteinuria and an in-creasing serum creatinine level. Eclampsia is the addition of grand mal sei-zures to preeclampsia.
The breadth of symptoms that can be attributed to severe preeclampsia makes it clear that distinguishing it from active lupus is diﬃcult and, insome situations, impossible. outlines some risk factors, laboratory,and physical ﬁndings that may clarify the diagnosis. Prior lupus nephritisincreases the risk for both a renal SLE ﬂare in pregnancy as well aspreeclampsia.
Treatment of systemic lupus erythematosus in pregnancy All pregnant women should take a prenatal multivitamin with at least 400 mg of folic acid each day. Folic acid supplementation is very important forwomen who have taken methotrexate before pregnancy, because folate de-ﬁciency can lead to neural tube defects ).
Prevention of systemic lupus erythematosus activity The best prevention of SLE ﬂares during pregnancy is the delay of con- ception until a woman has had quiescent SLE for at least 6 months. In manysituations, however, this is not possible. The continuation of medications forSLE during pregnancy helps to prevent SLE ﬂares.
Many women with SLE will be taking hydroxychloroquine (HCQ) (Pla- quenil) before pregnancy. This medication has been proven to decrease therisk of SLE ﬂare, improve the prognosis of SLE nephritis, and prevent death. It is also very well tolerated with arguably the best side-eﬀect proﬁleof any medication available to treat SLE. An expert panel, comprised of 29 Table 4Medications to prevent and treat lupus activity in pregnancy second trimester only.
Discontinue use in thirdtrimester.
pregnancy or to treat mildﬂares in pregnancy.
a FDA pregnancy risk categories: A, no risk in controlled clinic trials of humans; B, human data reassuring or when absent, animal studies show no risk; C, human data are lacking andanimal studies show risk or are not done; D, positive evidence of risk but the beneﬁt may out-weigh the risks; X, contraindicated in pregnancy.
international leaders in the research and care of women with SLE, recentlyrecommended the continuation of HCQ during pregnancy Amongmore than 300 pregnancies described in the literature that were exposedto HCQ for the treatment of autoimmune disease, there has been no eleva-tion of fetal anomalies identiﬁed. When chloroquine is taken at suprathera-peutic doses, there may be ocular or auditory damage. However, no suchchanges were seen among 133 babies exposed to HCQ in utero .
In nonpregnant SLE patients, the cessation of HCQ is associated with a 2-fold risk of SLE ﬂare within the following 6 months Amongpregnant SLE patients, as well, the risk for ﬂare increases when HCQ useis discontinued. In the Hopkins Lupus Pregnancy Cohort, 38 womendiscontinued HCQ use just before or early in pregnancy because of concernabout fetal exposure, and 56 women continued HCQ therapy throughoutpregnancy (. Among women who discontinued the medication,the risk for increased lupus activity, whether measured by absolutephysician’s estimate of activity, change in this scale, or the SLEDAI, was Table 5Lupus activity during pregnancy based on the use of hydroxychloroquine Abbreviation: PEA, physician’s estimate of activity.
Data from Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus preg- nancy. Arthritis Rheum 2006;54(11):3640–7.
signiﬁcantly increased. More of these women required corticosteroid ther-apy at higher doses than women who continued taking HCQ. Within thiscohort, as in other reports, there was no increase in fetal abnormalities afterHCQ exposure. The pregnancy outcomes among women who continued anddiscontinued taking HCQ were similar. This likely reﬂects the type of SLEactivity that women who discontinued taking HCQ suﬀered: they did nothave increased rates of lupus nephritis, anemia, or thrombocytopenia. In-stead, women who discontinued taking HCQ had increased incidence of fa-tigue and joint symptoms. Although these symptoms are uncomfortable,they are generally not life threatening nor do they require cytotoxic therapy.
They may, however, prompt the institution or increase of corticosteroidtherapy mid-pregnancy.
Azathioprine (Imuran) may be the safest immunosuppressant medication taken during pregnancy. The fetal liver does not have the enzyme requiredto metabolize azathioprine into its active form . A report of three womenwho took azathioprine throughout pregnancy for inﬂammatory bowel dis-ease or autoimmune hepatitis showed comparable levels of 6-thioguaninenu-cleoties (6-TGN) but no evidence of 6-methylmercaptopurine (6-MMP) infetal blood at the time of delivery . The level of 6-TGN is associatedwith myelosuppression in adults, and may rarely prompt transient myelo-suppression after in utero exposure . Series of pregnancies exposed toazathioprine for inﬂammatory bowel disease or renal transplants show nosigniﬁcant increase in fetal abnormalities Among renal transplant pa-tients, however, up to 40% of the oﬀspring were small for gestational age.
It is not clear if this was a product of the underlying illness, corticosteroids,or azathioprine use .
Little data are available about the use of azathioprine in SLE pregnancy.
In the Hopkins Lupus Pregnancy Cohort, 31 pregnancies were exposed toazathioprine . Among the women who conceived while taking azathio-prine and continued it through pregnancy, 2 of the 13 ended in a pregnancyloss, both in women who had active SLE in pregnancy. Among the 10women who maintained low lupus activity and azathioprine throughout pregnancy, all resulted in live births at greater than 34 weeks’ gestation.
Based on these data, we recommend the continuation of azathioprine treat-ment throughout pregnancy if the woman required it before pregnancy totreat her lupus. We also recommend switching women from mycophenolatemofetil (MMF) to azathioprine therapy before conception to avoid theteratogenic eﬀects of the MMF.
Treatment of systemic lupus erythematosus ﬂares during pregnancy Women without any signs or symptoms of active SLE require no speciﬁc treatment during pregnancy. Prior recommendations for prophylactic corti-costeroids have been rescinded because of increased hypertension, pretermbirth, and low birth weight seen with excess use of this medication.
Mild activity can be treated with low-dose prednisone (less than 20 mg/d) as required. The side eﬀects of low-dose corticosteroids include increasedrisk for hypertension and diabetes, just as in a nonpregnant woman. Theremay be a 2-fold increased risk for cleft lip or palate with systemic corticoste-roid use, although the absolute risk for this remains low (about 20 per10,000 babies with corticosteroid exposure) .
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) can be used during the latter part of the ﬁrst trimester and during the second trimester. There isevidence in a murine model that COX enzymes are important for embryoimplantation, which may explain the increased risk for early miscarriagein women taking NSAIDs around the time of conception .
NSAIDs are considered fairly safe in the second trimester, although theymay decrease fetal renal excretion and therefore promote oligohydramnios. NSAIDs should be stopped in the third trimester for 2 reasons:they can prolong labor and may promote premature closure of the ductusarteriosis Moderate lupus activity can be treated with higher doses of corticoste- roids, including pulse–dose steroids. Only a small percentage of each doseof prednisone and prednisolone cross the maternal–fetal membranes. How-ever, ﬂuorinated glucocorticoids, such as dexamethasone and betametha-sone, easily transfer to the fetus. These steroids can be helpful in treatingthe fetus, in particular in promoting fetal lung maturity before a preterm de-livery. However, they have also been associated with lasting adverse eﬀectson the oﬀspring. Children exposed to these corticosteroids may have in-creased blood pressure and cognitive deﬁcits Therefore, dexametha-sone and betamethasone should not be used to treat lupus activity duringpregnancy.
The commencement of azathioprine mid-pregnancy for a lupus ﬂare may be risky. In the Hopkins Lupus Pregnancy Cohort there was an increase inpregnancy loss among woman who used azathioprine to treat a moderate tosevere ﬂare: of the 8 pregnancies with moderate to severe ﬂare treated withazathioprine, ﬁve (63%) resulted in a pregnancy loss, whereas only 1 of 9 (11%) of those with severe SLE activity but treated without azathioprinewere lost (P ¼ .02) Another option for treatment mid-pregnancy is intravenous immunoglo- bin (IVIg). IVIg can be particularly helpful in controlling hematologic and re-nal disease There are no published series of IVIg use for lupus duringpregnancy; however, there are multiple reports of IVIg use to prevent recur-rent miscarriage. In these cases, the primary outcome is live birth, and there isno change in this rate with the use of IVIg. Little has been published on theeﬀects of IVIg on the oﬀspring, but cell count levels seem to be stable, andno congenital anomalies have been reported. IVIg that contains sucrosecan prompt renal insuﬃciency, but this has not hampered the treatment ofnonpregnant women with lupus nephritis Some women will have head-aches, rigors, or fevers with IVIg therapy, but more severe side eﬀects are rare.
Cyclophosphamide (Cytoxan) and MMF (Cellcept) should be avoided during pregnancy. First trimester exposure to cyclophosphamide causes fe-tal abnormalities in a signiﬁcant minority of patients. Exposure in the sec-ond and third trimesters does not increase the risk for fetal anomaliesamong women treated for breast cancer during pregnancy. Of the threepregnancies women with SLE who had cyclophosphamide treatment duringmid-pregnancy reported in the literature, however, only one resulted ina live birth . Cyclophosphamide should only be used when all otheroptions are exhausted, and a frank a discussion about the risk for pregnancyloss has been discussed with the mother. The data on MMF in pregnancyare scarce but worrisome. There appears to be an elevated risk for both fetalanomalies and pregnancy losses .
The hormonal and physiologic changes that occur in pregnancy can in- duce lupus activity. Likewise, the increased inﬂammatory response duringa lupus ﬂare can cause signiﬁcant pregnancy complications. Distinguishingbetween lupus activity and signs of both healthy and pathologic pregnancycan be diﬃcult. A rheumatologist and a high-risk obstetrician are bestequipped to care for women with lupus who become pregnant. Fortunately,most women with lupus remain well throughout pregnancy and deliverhealthy babies. However, careful planning and treatment may be requiredto achieve this success.
 Clowse MEB, Jamison MG, Myers E, et al. National study of medical complications in SLE pregnancies. Arthritis Rheum 2006;54(9 Suppl):S263–4.
 Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54(3):899–907.
 Clark CA, Spitzer KA, Nadler JN, et al. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30(10):2127–32.
 Cohen-Solal JF, Jeganathan V, Grimaldi CM, et al. Sex hormones and SLE: inﬂuencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 2006;305:67–88.
 Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr Opin Rheumatol 2006;18(5):456–61.
 Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis  Meehan RT, Dorsey JK. Pregnancy among patients with systemic lupus erythematosus re- ceiving immunosuppressive therapy. J Rheumatol 1987;14(2):252–8.
 Urowitz MB, Gladman DD, Farewell VT, et al. Lupus and pregnancy studies. Arthritis  Tincani A, Faden D, Tarantini M, et al. Systemic lupus erythematosus and pregnancy: a pro- spective study. Clin Exp Rheumatol 1992;10(5):439–46.
 Petri M. Hopkins Lupus Pregnancy Center: 1987 to 1996. Rheum Dis Clin North Am 1997;  Lima F, Buchanan NM, Khamashta MA, et al. Obstetric outcome in systemic lupus eryth- ematosus. Semin Arthritis Rheum 1995;25(3):184–92.
 Carmona F, Font J, Cervera R, et al. Obstetrical outcome of pregnancy in patients with sys- temic lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod Biol 1999;83(2):137–42.
 Cortes-Hernandez J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheuma-tology (Oxford) 2002;41(6):643–50.
 Chakravarty EF, Colon I, Langen ES, et al. Factors that predict prematurity and preeclamp- sia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gy-necol 2005;192(6):1897–904.
 Rubbert A, Pirner K, Wildt L, et al. Pregnancy course and complications in patients with systemic lupus erythematosus. Am J Reprod Immunol 1992;28(3–4):205–7.
 Clowse ME, Magder LS, Witter F, et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52(2):514–21.
 Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis  Georgiou PE, Politi EN, Katsimbri P, et al. Outcome of lupus pregnancy: a controlled study.
Rheumatology (Oxford) 2000;39(9):1014–9.
 Petri M, Howard D, Repke J, et al. The Hopkins Lupus Pregnancy Center: 1987–1991 up- date. Am J Reprod Immunol 1992;28(3–4):188–91.
 Wong KL, Chan FY, Lee CP. Outcome of pregnancy in patients with systemic lupus eryth- ematosus. A prospective study. Arch Intern Med 1991;151(2):269–73.
 Clowse ME, Magder LS, Witter F, et al. Early risk factors for pregnancy loss in lupus. Obstet  Yasmeen S, Wilkins EE, Field NT, et al. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001;10(2):91–6.
 Johnson MJ, Petri M, Witter FR, et al. Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic. Obstet Gynecol 1995;86(3):396–9.
 Magid MS, Kaplan C, Sammaritano LR, et al. Placental pathology in systemic lupus eryth- ematosus: a prospective study. Am J Obstet Gynecol 1998;179(1):226–34.
 Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996;87(2):163–8.
 Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol  Qazi UM, Petri M. Autoantibodies, low complement, and obesity predict preeclampsia in SLE: a case-control study. Arthritis Rheum 2006;54(9 Suppl):S264.
 Qazi UM, Lam C, Karumanchi A, et al. Soluble FMS-like tyrosine kinase is a signiﬁcant pre- dictor of preeclampsia in SLE pregnancy. Arthritis Rheum 2006;54(9 Suppl):S264–5.
 Julkunen H, Kaaja R, Palosuo T, et al. Pregnancy in lupus nephropathy. Acta Obstet Gyne-  Huong DL, Wechsler B, Vauthier-Brouzes D, et al. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 2001;60(6):599–604.
 Moroni G, Quaglini S, Banﬁ G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis 2002;  Jungers P, Dougados M, Pelissier C, et al. Lupus nephropathy and pregnancy. Report of 104 cases in 36 patients. Arch Intern Med 1982;142(4):771–6.
 Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis.
 Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE pa- tients during pregnancy. Lupus 1999;8(8):677–84.
 De Man YA, Hazes JMW, Van de Geijn FE, et al. How to measure functionality and disease activity during pregnancy in rheumatoid arthritis patients. Ann Rheum Dis 2005;64(SupplIII):196.
 Ostensen M, Rugelsjoen A, Wigers SH. The eﬀect of reproductive events and alterations of sex hormone levels on the symptoms of ﬁbromyalgia. Scand J Rheumatol 1997;26(5):355–60.
 Ho A, Barr SG, Magder LS, et al. A decrease in complement is associated with increased re- nal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum2001;44(10):2350–7.
 Buyon JP, Tamerius J, Ordorica S, et al. Activation of the alternative complement pathway accompanies disease ﬂares in systemic lupus erythematosus during pregnancy. ArthritisRheum 1992;35(1):55–61.
 Clowse MEB, Magder LS, Petri M. Complement and double-stranded DNA antibodies pre- dict pregnancy outcomes in lupus patients. Arthritis Rheum 2004;50(9 Suppl):S408.
 Pitiphat W, Gillman MW, Joshipura KJ, et al. Plasma C-reactive protein in early pregnancy and preterm delivery. Am J Epidemiol 2005;162(11):1108–13.
 Hesselink DA, Aarden LA, Swaak AJ. Proﬁles of the acute-phase reactants C-reactive pro- tein and ferritin related to the disease course of patients with systemic lupus erythematosus.
Scand J Rheumatol 2003;32(3):151–5.
 Williams RC Jr, Harmon ME, Burlingame R, et al. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 2005;32(3):454–61.
 ter Borg EJ, Horst G, Limburg PC, et al. C-reactive protein levels during disease exacerba- tions and infections in systemic lupus erythematosus: a prospective longitudinal study.
J Rheumatol 1990;17(12):1642–8.
 Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal re- mission within 12 months among patients treated with mycophenolate mofetil therapy formembranous lupus nephritis. Lupus 2006;15(6):366–70.
 Alarcon GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort.
LUMINA Study Group. Arthritis Rheum 2001;45(2):191–202.
 The Canadian Hydroxychloroquine Study Group. A randomized study of the eﬀect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med1991;324(3):150–4.
 Ostensen M, Khamashta M, Lockshin M, et al. Anti-inﬂammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8(3):209–28.
 Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in preg- nant patients with connective tissue diseases: a study of one hundred thirty-three cases com-pared with a control group. Arthritis Rheum 2003;48(11):3207–11.
 de Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unex- pected intrauterine exposure to metabolites. Am J Gastroenterol 2006;101(6):1390–2.
 Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and de- pressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985;92(3):233–9.
 Miniero R, Tardivo I, Curtoni ES, et al. Pregnancy after renal transplantation in Italian pa- tients: focus on fetal outcome. J Nephrol 2002;15(6):626–32.
 Clowse MEB, Magder LS, Witter F, et al. Azathioprine use in lupus pregnancy. Arthritis  Canﬁeld MA, Honein MA, Yuskiv N, et al. National estimates and race/ethnic-speciﬁc var- iation of selected birth defects in the United States, 1999–2001. Birth Defects Res A Clin MolTeratol 2006;76(11):747–56.
 Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 2003;67(12):968–70.
 Scherle PA, Ma W, Lim H, et al. Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy. J Biol Chem 2000;275(47):37086–92.
 Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inﬂammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003;327(7411):368–78.
 Topuz S, Has R, Ermis H, et al. Acute severe reversible oligohydramnios induced by indo- methacin in a patient with rheumatoid arthritis: a case report and review of the literature.
Clin Exp Obstet Gynecol 2004;31(1):70–2.
 Holmes RP, Stone PR. Severe oligohydramnios induced by cyclooxygenase-2 inhibitor ni- mesulide. Obstet Gynecol 2000;96(5 Pt 2):810–1.
 Whitelaw A, Thoresen M. Antenatal steroids and the developing brain. Arch Dis Child Fetal  Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003;62(10):1010–2.
 Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and sys- temic lupus erythematosus. Clin Rev Allergy Immunol 2005;29(3):219–28.
 Rauova L, Lukac J, Levy Y, et al. High-dose intravenous immunoglobulins for lupus nephri- tis–a salvage immunomodulation. Lupus 2001;10(3):209–13.
 Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus  Kart Koseoglu H, Yucel AE, Kunefeci G, et al. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 2001;10(11):818–20.
dEL doMiNGo 2 AL SáBAdo 8 dE ENERo dE 2011 35 años, pero es entre 65 y 74 años donde se encuentran las diferencias más destacadas (88,6% en hombres y 81,5% en mujeres). También exis-ten diferencias en las frecuencias de medición del colesterol por clase so-cial, siendo las personas de las cla-ses sociales más altas quienes con más frecuencia se han hecho algu-na medición